SEC Form 4 · accession 0001493152-26-043559
Nasus Pharma Ltd · NSRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eyal Rubin
Officer — Chief Financial Officer · Other
Period of report
Sep 18, 2026
Accepted (ET)
Sep 21, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002029039
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
No Table II lines on this filing.
Remarks
This Exit Form 4 has been filed solely to report that Reporting Person ceased to serve as the Chief Financial Officer and Executive Vice President of Nasus Pharma Ltd (the "Issuer"), effective as of September 18, 2026, and is no longer subject to the reporting obligations under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to the Issuer.